- GLPG stock hit hard by COVID-19 Panic, though its outlook not directly affected

- Bulls expect rheumatoid arthritis treatment to be approved by FDA in 2H20

- Peak sales could be $4 billion-$6 billion; If achieved we believe stock could double

As I’ve noted in previous reports, the healthcare sector can be a calm port in the coronavirus storm. I look for stock ideas that offer short term ballast for a portfolio in tough times but which also have potential for long term outperformance.

The video in this report is only accessible to members

Galapagos (GLPG), a Belgium-based healthcare firm whose shares trade in the U.S, is looking at the likely arrival in 2020 of important results from a number of different studies and, more importantly, a potential drug approval from the Food & Drug Administration for its most important product currently: filgotinib.

It has already shown promise in Phase 3 trials for treatment of rheumatoid arthritis (RA), a chronic autoimmune disease that affects about three million people in the U.S. and Europe and millions more worldwide. GLPG bulls expect FDA approval in the fall. (More on this below.)  Despite its whimsical name, Galapagos has nothing to do with the island made famous by Darwin and much to do with a potential to bring various t...

Unlock this article with a FREE 30-Day Trial!

An FSI Pro, or FSI Macro subscription is required in order to access this content.

*Free trial available only on a monthly plan

Disclosures (show)

Get invaluable analysis of the market and stocks. Cancel at any time. Start Free Trial

Articles Read 2/2

🎁 Unlock 1 extra article by joining our Community!

You’ve reached your limit of 2 free monthly articles. Please enter your email to unlock 1 more articles.

Already have an account? Sign In

Want to receive Regular Market Updates to your Inbox?

I am your default error :)